Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Experimental basis for myocardial imaging with /sup 123/I-labeled hexadecnoic acid. [/sup 11/C, /sup 43/K]

Journal Article · · J. Nucl. Med.; (United States)
OSTI ID:7236791

Progress in myocardial perfusion imaging has been slowed by the lack of radiopharmaceuticals with suitable physical and biologic characteristics. Hexadecanoic acid, terminally labeled with /sup 123/I, partially overcomes these limitations by providing a compound that concentrates in the myocardium in proportion to relative regional blood flow and carries a gamma-emitter with desirable detection and imaging qualities. After intravenous injection in experimental animals, the clearance half-times of hexadecanoic acid for blood and myocardium are 1.7 and 20 min, respectively. These values compare favorably with 18-carbon fatty-acid analogs labeled with /sup 11/C. In acute and chronic infarction, similar distribution patterns are found for hexadecenoic acid and /sup 43/K, which indicates that hexadecenoic acid is a suitable substitute for the potassium analogs now in use for myocardial imaging. Because of the high count rates obtainable with /sup 123/I-hexadecanoic acid, good-quality images can be acquired in as little as 2--3 min per view. Iodine-123-hexadecanoic acid is potentially a useful radiopharmaceutical for clinical application.

Research Organization:
Univ. of California, Los Angeles
OSTI ID:
7236791
Journal Information:
J. Nucl. Med.; (United States), Journal Name: J. Nucl. Med.; (United States) Vol. 17:12; ISSN JNMEA
Country of Publication:
United States
Language:
English